David Hallal Sells 38,227 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) Stock

iTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) Director David Hallal sold 38,227 shares of the firm's stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $10.15, for a total transaction of $388,004.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

David Hallal also recently made the following trade(s):

• On Friday, June 6th, David Hallal sold 38,228 shares of iTeos Therapeutics stock. The stock was sold at an average price of $10.24, for a total value of $391,454.72.

iTeos Therapeutics Stock Down 0.1%

iTeos Therapeutics stock traded down $0.01 during mid-day trading on Friday, hitting $10.17. The company had a trading volume of 1,062,628 shares, compared to its average volume of 658,136. The business has a fifty day moving average of $7.38 and a 200 day moving average of $7.47. The stock has a market cap of $389.25 million, a price-to-earnings ratio of -3.23 and a beta of 1.39. iTeos Therapeutics, Inc. has a 1 year low of $4.80 and a 1 year high of $18.13.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last posted its earnings results on Monday, April 28th. The company reported ($0.80) EPS for the quarter, topping analysts' consensus estimates of ($0.94) by $0.14. Equities analysts anticipate that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current year.

Institutional Trading of iTeos Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. BVF Inc. IL purchased a new position in shares of iTeos Therapeutics in the fourth quarter worth approximately $17,856,000. JPMorgan Chase & Co. boosted its position in shares of iTeos Therapeutics by 342.7% in the fourth quarter. JPMorgan Chase & Co. now owns 2,068,796 shares of the company's stock valued at $15,888,000 after acquiring an additional 1,601,477 shares during the period. RA Capital Management L.P. lifted its stake in shares of iTeos Therapeutics by 74.4% in the first quarter. RA Capital Management L.P. now owns 3,649,057 shares of the company's stock valued at $21,785,000 after buying an additional 1,556,798 shares during the period. Boxer Capital Management LLC bought a new position in iTeos Therapeutics in the fourth quarter worth $7,272,000. Finally, 683 Capital Management LLC lifted its position in shares of iTeos Therapeutics by 90.6% during the 1st quarter. 683 Capital Management LLC now owns 1,750,000 shares of the company's stock worth $10,448,000 after buying an additional 831,883 shares during the period. 97.16% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ITOS. Raymond James set a $12.00 price objective on shares of iTeos Therapeutics in a research note on Wednesday, May 14th. Wedbush downgraded iTeos Therapeutics from an "outperform" rating to a "neutral" rating and upped their target price for the company from $10.00 to $12.00 in a report on Wednesday, May 28th. Leerink Partnrs cut iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, May 14th. HC Wainwright downgraded iTeos Therapeutics from a "buy" rating to a "neutral" rating in a report on Wednesday, May 14th. Finally, Wells Fargo & Company reiterated an "equal weight" rating and issued a $12.00 price target (down from $13.00) on shares of iTeos Therapeutics in a research report on Wednesday, May 28th. Six research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $15.86.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.